IBRX Stock: Price, Earnings History and SEC Filings
ImmunityBio, Inc. (IBRX) last traded at $8.29, down 5.15% on the latest session and down 12.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.08 against an analyst estimate of $-0.09, a beat of 11.1%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IBRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.08 | $-0.09 | +11.11% |
| Mar 2026 | May 7, 2026 | $-0.09 | $-0.08 | -12.50% |
| Dec 2025 | Feb 23, 2026 | $-0.06 | $-0.08 | +25.00% |
| Sep 2025 | Nov 4, 2025 | $-0.07 | $-0.10 | +30.00% |
IBRX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How IBRX reacts to earnings
Across its last 8 earnings releases, IBRX moved 8.7% on average the next session, in either direction. It rose after 4 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | Before open | -2.80% |
| 2026-05-07 | Before open | -7.40% |
| 2026-04-09 | Before open | +7.16% |
| 2026-02-23 | Before open | +12.99% |
| 2026-01-15 | Before open | +30.79% |
| 2025-11-04 | After close | +3.37% |
| 2025-08-05 | Before open | +0.00% |
| 2025-07-25 | Before open | -4.98% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
IBRX financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $113M | -$351M | -$309M | -310.2% | $-0.38 |
| 2024 | $15M | -$414M | -$398M | -2804.8% | $-0.62 |
| 2023 | $622000 | -$583M | -$397M | -93761.4% | $-1.15 |
| 2022 | $240000 | -$417M | -$416M | -173569.6% | $-1.04 |
| 2021 | $934000 | -$347M | -$308M | -37129.6% | $-0.89 |
| 2020 | $605000 | -$222M | -$173M | -36669.6% | $-0.59 |
| 2019 | $2M | -$158M | -$156M | -7165.2% | $-0.43 |
| 2018 | $47000 | -$96M | -$76M | -204736.2% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for IBRX
- 8-K · Oct 14, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 4, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jul 30, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 10, 2026Shareholder vote, Financial statements and exhibits
- 8-K · May 18, 2026Material agreement, Regulation FD disclosure, Financial statements and exhibits
- 10-Q · May 7, 2026
- 8-K · May 7, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 30, 2026
- 8-K · Apr 9, 2026Results of operations, Financial statements and exhibits
Insider filing activity
IBRX insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
IBRX news
- SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3Oct 30, 2026 · stocktwits.com
- Insmed (INSM) Reports Q3 Loss, Tops Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Prime Medicine, Inc. (PRME) Surges 23.2%: Is This an Indication of Further Gains?Oct 29, 2026 · finance.yahoo.com
- IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover WaveOct 27, 2026 · stocktwits.com
- Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year?Oct 22, 2026 · finance.yahoo.com
- ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing NearsOct 21, 2026 · stocktwits.com
- ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder CancerOct 21, 2026 · finance.yahoo.com
- ANKTIVA Label Expansion Could Change The Case For ImmunityBio StockOct 19, 2026 · finance.yahoo.com
About ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.